Intralymfatisk allergenspecifik immunterapi

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Intralymfatisk allergenspecifik immunterapi. / Næraa, Sara Haunstrup; Schollert, Niels-Erik Harbo; Flader Skov, Peter Nytofte; Homøe, Preben.

In: Ugeskrift for Laeger, Vol. 180, No. 22, V09170695, 2018.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Næraa, SH, Schollert, N-EH, Flader Skov, PN & Homøe, P 2018, 'Intralymfatisk allergenspecifik immunterapi', Ugeskrift for Laeger, vol. 180, no. 22, V09170695. <http://ugeskriftet.dk/videnskab/intralymfatisk-allergenspecifik-immunterapi>

APA

Næraa, S. H., Schollert, N-E. H., Flader Skov, P. N., & Homøe, P. (2018). Intralymfatisk allergenspecifik immunterapi. Ugeskrift for Laeger, 180(22), [V09170695]. http://ugeskriftet.dk/videnskab/intralymfatisk-allergenspecifik-immunterapi

Vancouver

Næraa SH, Schollert N-EH, Flader Skov PN, Homøe P. Intralymfatisk allergenspecifik immunterapi. Ugeskrift for Laeger. 2018;180(22). V09170695.

Author

Næraa, Sara Haunstrup ; Schollert, Niels-Erik Harbo ; Flader Skov, Peter Nytofte ; Homøe, Preben. / Intralymfatisk allergenspecifik immunterapi. In: Ugeskrift for Laeger. 2018 ; Vol. 180, No. 22.

Bibtex

@article{d1aaa80e84c74dcd9b0f9dd46786d7c2,
title = "Intralymfatisk allergenspecifik immunterapi",
abstract = "An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions. The immunological activation profile is comparable to that known for subcutaneous therapy. Clinically, patients experienced fewer symptoms with less medication use with intralymphatic allergen-specific immunotherapy than with other types of immunotherapy. The number of studies is limited, and the studies have important limitations. More phase 3 studies are needed in order to make a conclusion.",
author = "N{\ae}raa, {Sara Haunstrup} and Schollert, {Niels-Erik Harbo} and {Flader Skov}, {Peter Nytofte} and Preben Hom{\o}e",
year = "2018",
language = "Dansk",
volume = "180",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "22",

}

RIS

TY - JOUR

T1 - Intralymfatisk allergenspecifik immunterapi

AU - Næraa, Sara Haunstrup

AU - Schollert, Niels-Erik Harbo

AU - Flader Skov, Peter Nytofte

AU - Homøe, Preben

PY - 2018

Y1 - 2018

N2 - An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions. The immunological activation profile is comparable to that known for subcutaneous therapy. Clinically, patients experienced fewer symptoms with less medication use with intralymphatic allergen-specific immunotherapy than with other types of immunotherapy. The number of studies is limited, and the studies have important limitations. More phase 3 studies are needed in order to make a conclusion.

AB - An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions. The immunological activation profile is comparable to that known for subcutaneous therapy. Clinically, patients experienced fewer symptoms with less medication use with intralymphatic allergen-specific immunotherapy than with other types of immunotherapy. The number of studies is limited, and the studies have important limitations. More phase 3 studies are needed in order to make a conclusion.

M3 - Tidsskriftartikel

C2 - 29808813

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 22

M1 - V09170695

ER -

ID: 222248033